Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Genomics & Proteomics
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Cancer Genomics & Proteomics

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleArticles
Open Access

Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders

MARIA PAGONI, VASILEIOS L. ZOGOPOULOS, STAVROS KONTOGIANNIS, ANNIA TSOLAKOU, VASSILIOS ZOUMPOURLIS, GEORGE TH. TSANGARIS, ELEFTHERIOS FOKAEFS, IOANNIS MICHALOPOULOS, ARISTIDIS M. TSATSAKIS and NIKOLAOS DRAKOULIS
Cancer Genomics & Proteomics March 2025, 22 (2) 285-305; DOI: https://doi.org/10.21873/cgp.20502
MARIA PAGONI
1Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: maria.pagoni{at}pharm.uoa.gr gthtsangaris{at}bioacademy.gr
VASILEIOS L. ZOGOPOULOS
2Centre of Systems Biology, Biomedical Research Foundation, Academy of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STAVROS KONTOGIANNIS
3Department of Urology, Patras University Hospital, Patras, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNIA TSOLAKOU
1Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VASSILIOS ZOUMPOURLIS
4National Hellenic Research Foundation, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGE TH. TSANGARIS
5Proteomics Research Unit, Biomedical Research Foundation, Academy of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: maria.pagoni{at}pharm.uoa.gr gthtsangaris{at}bioacademy.gr
ELEFTHERIOS FOKAEFS
3Department of Urology, Patras University Hospital, Patras, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IOANNIS MICHALOPOULOS
2Centre of Systems Biology, Biomedical Research Foundation, Academy of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ARISTIDIS M. TSATSAKIS
6Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKOLAOS DRAKOULIS
1Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 22 no. 2 285-305
DOI 
https://doi.org/10.21873/cgp.20502
PMID 
39993800

Published By 
International Institute of Anticancer Research
Print ISSN 
1109-6535
Online ISSN 
1790-6245
History 
  • Received December 20, 2024
  • Revision received January 14, 2025
  • Accepted January 16, 2025
  • Published online February 24, 2025.

Copyright & License 
Copyright © 2025 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

  1. MARIA PAGONI1⇑,
  2. VASILEIOS L. ZOGOPOULOS2,
  3. STAVROS KONTOGIANNIS3,
  4. ANNIA TSOLAKOU1,
  5. VASSILIOS ZOUMPOURLIS4,
  6. GEORGE TH. TSANGARIS5⇑,
  7. ELEFTHERIOS FOKAEFS3,
  8. IOANNIS MICHALOPOULOS2,
  9. ARISTIDIS M. TSATSAKIS6 and
  10. NIKOLAOS DRAKOULIS1
  1. 1Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece;
  2. 2Centre of Systems Biology, Biomedical Research Foundation, Academy of Athens, Athens, Greece;
  3. 3Department of Urology, Patras University Hospital, Patras, Greece;
  4. 4National Hellenic Research Foundation, Athens, Greece;
  5. 5Proteomics Research Unit, Biomedical Research Foundation, Academy of Athens, Athens, Greece;
  6. 6Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece
  1. Maria Pagoni, Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15771 Athens, Greece. Tel: +30 2107274149, e-mail: maria.pagoni{at}pharm.uoa.gr and George Th. Tsangaris, Proteomics Research Unit, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece. Tel: +30 2106597075, e-mail: gthtsangaris{at}bioacademy.gr
View Full Text

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Cancer Genomics - Proteomics: 22 (2)
Cancer Genomics & Proteomics
Vol. 22, Issue 2
March-April 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cancer Genomics & Proteomics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders
(Your Name) has sent you a message from Cancer Genomics & Proteomics
(Your Name) thought you would like to see the Cancer Genomics & Proteomics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 16 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders
MARIA PAGONI, VASILEIOS L. ZOGOPOULOS, STAVROS KONTOGIANNIS, ANNIA TSOLAKOU, VASSILIOS ZOUMPOURLIS, GEORGE TH. TSANGARIS, ELEFTHERIOS FOKAEFS, IOANNIS MICHALOPOULOS, ARISTIDIS M. TSATSAKIS, NIKOLAOS DRAKOULIS
Cancer Genomics & Proteomics Mar 2025, 22 (2) 285-305; DOI: 10.21873/cgp.20502

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders
MARIA PAGONI, VASILEIOS L. ZOGOPOULOS, STAVROS KONTOGIANNIS, ANNIA TSOLAKOU, VASSILIOS ZOUMPOURLIS, GEORGE TH. TSANGARIS, ELEFTHERIOS FOKAEFS, IOANNIS MICHALOPOULOS, ARISTIDIS M. TSATSAKIS, NIKOLAOS DRAKOULIS
Cancer Genomics & Proteomics Mar 2025, 22 (2) 285-305; DOI: 10.21873/cgp.20502
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Noggin Promotes Cell Proliferation Through Up-regulating EGFR/HER2 in Pancreatic Cancer Cells
  • Prognostic Significance of EZH2-Related Gene Variants in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
  • Elevated Stanniocalcin-1 Expression in Uveal Melanoma Predicts Poor Patient Prognosis
Show more Articles

Keywords

  • Pharmacogenetics
  • epigenetics
  • metabolomics
  • prostatic neoplasia
  • PCa
  • BPH
  • diabetes
  • dislipidemia
  • hypertension
  • steroid hormone pathway
  • FoxO signaling pathway
  • p53 signaling pathway
  • estrogen signaling pathway
  • CYP3A4
  • miRNAs
Cancer & Genome Proteomics

© 2026 Cancer Genomics & Proteomics

Powered by HighWire